OBJECTIVE To report a case of acute myopathy after concomitant use of colchicine and
pravastatin. CASE SUMMARY A 65-year-old woman was admitted to the hospital with an …

Abstract Colchicine and 3-hydroxy-3-methy-glutaryl coenzyme A (HMG-CoA) reductase
inhibitors are well known to cause myopathy. Myotoxicity is dose-dependent in both drugs; …

We report a case of a patient with mild chronic renal insufficiency who had been taking
simvastatin for over a year and developed acute weakness within 3 weeks after the start of …

We report the case of a 79‐year‐old man with mild chronic renal failure who developed
severe rhabdomyolysis after combined exposure to simvastatin and colchicine. Colchicine …

Simvastatin is among the most commonly used prescription medications for cholesterol
reduction and the most common statin‐related adverse drug reaction is skeletal muscle …

Discussion Two different mechanisms may be responsible for the pathogenesis in our
patient. Drug interactions that potentiate adverse effects may occur when colchicine is …

OBJECTIVE: To report a case of severe myopathy associated with concomitant simvastatin
and amiodarone therapy. CASE SUMMARY: A 63-year-old white man with underlying …

A case of acute inflammatory myopathy associated with the use of pravastatin, a new
hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported. The …

Simvastatin is an inhibitor of 3-hydroxy3-methylglutaryl coenzyme A (HMG-CoA) reductase
that is used as a cholesterol-lowering agent and is metabolized by cytochrome P-450^ sub …

The hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely
used hypolipidemic agents which decrease cardiovascular morbidity and mortality in both …